Literature DB >> 3183748

Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.

M Schlumberger1, O Arcangioli, J D Piekarski, M Tubiana, C Parmentier.   

Abstract

Lung metastases were demonstrated by total-body 131I scans in 23 patients with differentiated thyroid carcinoma, at a time when chest x-ray was normal. This total-body 131I scan was performed after the administration of 2 mCi (in 11 patients) or 100 mCi (in 12 patients). Overall uptake of 131I in lungs was less than 1% of the administered dose in 11 patients. All patients were treated with radioiodine. No lung uptake was found in 20 patients at the last 100 mCi post-therapy scan. Among them, Tg level became undetectable during T4 treatment in eight, lung CT scan showed the disappearance of the micronodules in seven, and lung biopsy did not show evidence of disease in two patients. No patient developed radiation lung fibrosis. In conclusion, favorable responses to radioiodine treatment were observed despite relatively low overall uptake, in relation to the small size of lung metastases. This provides high concentrations of radioiodine and therefore high radiation doses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183748

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  32 in total

1.  Management of thyroglobulin-positive, body scan-negative thyroid cancer patients: evidence for the utility of I-131 therapy.

Authors:  J Robbins
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 2.  The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer.

Authors:  M C Skarulis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

3.  Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?

Authors:  C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07       Impact factor: 9.236

4.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

5.  Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer.

Authors:  Hussam M Binyousef; Ali S Alzahrani; Saif S Al-Sobhi; Suhaibani Hamed S Al; Mohammed A Chaudhari; Hussain M Raef
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

Review 6.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

7.  Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer.

Authors:  V Oliynyk; O Epshtein; T Sovenko; M Tronko; R Elisei; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 8.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

Review 9.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

10.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.